<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6512">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010932</url>
  </required_header>
  <id_info>
    <org_study_id>DGD-44-048</org_study_id>
    <nct_id>NCT01010932</nct_id>
  </id_info>
  <brief_title>Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)</brief_title>
  <official_title>Evaluation of Dotarem-enhanced MRA Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Carotid and Vertebral Basilar Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients
      suffering from carotid or vertebral arterial disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA)
      followed by a Dotarem enhanced MRA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Technical Failure Rate</measure>
    <time_frame>2 - 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-060).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>2-42 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of true stenotic segments (i.e. with stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>2 - 42 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of true non-stenotic segments (i.e. without stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity at Patient Level and at Segment Level Excluding Non-assessable Segments</measure>
    <time_frame>2-42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Predictive Values of Dotarem-enhanced MRA and TOF MRA at Patient Level and at Segment Level</measure>
    <time_frame>2 - 42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter and Intra-readers Agreement at the Segment Level</measure>
    <time_frame>2 -42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of the Different Reasons for Technical Failure for Both MRA Procedures</measure>
    <time_frame>2 -42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Images of Both MRA Procedures</measure>
    <time_frame>2 - 42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Diagnostic Confidence for Both MRA Procedures</measure>
    <time_frame>2 -42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of Stenoses for All Imaging Procedures (MRA and Gold Standard)</measure>
    <time_frame>2 -42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Examination</measure>
    <time_frame>2-42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of the Recommended Clinical Management</measure>
    <time_frame>2 -42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>0 - 42 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Sampling</measure>
    <time_frame>24 hours after Dotarem injection</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance at the Injection Site</measure>
    <time_frame>24 hours after Dotarem injection</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Cerebral Arterial Diseases</condition>
  <arm_group>
    <arm_group_label>Dotarem and TOF MRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dotarem</intervention_name>
    <description>Each subject will receive one injection of Dotarem 0.2ml/kg</description>
    <arm_group_label>Dotarem and TOF MRA</arm_group_label>
    <other_name>Gadoterate meglumine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TOF MRA</intervention_name>
    <description>Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)</description>
    <arm_group_label>Dotarem and TOF MRA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged more than 18 years

          -  Strongly suspected of having carotid or vertebral arterial disease

          -  Scheduled (or to be scheduled) to undergo computed tomography angiography (CTA)
             examination

        Exclusion Criteria:

          -  Known grade IV or V chronic kidney disease (GFR&lt;30 mL/min/1.73m²)

          -  Contraindication to MRI

          -  Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA
             examination
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre DESCHE, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guerbet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guerbet LLC</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 25, 2015</lastchanged_date>
  <firstreceived_date>November 9, 2009</firstreceived_date>
  <firstreceived_results_date>July 29, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carotid or vertebral artery disease</keyword>
  <keyword>Contrast agent</keyword>
  <keyword>MRA</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cerebral Arterial Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gadoterate meglumine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient first visit: 21 Sep 2009. Last patient last visit: 18 Nov 2010. Location: radiology departments</recruitment_details>
      <pre_assignment_details>A total of 222 patients fulfilling the eligibility criteria were enrolled, of which 200 patients received Dotarem and completed the study. Twenty-two patients did not receive Dotarem and were discontinued prematurely.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TOF MRA Followed by Dotarem-enhanced MRA</title>
          <description>Each patient will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem-enhanced MRA.
Each patient will be scheduled to undergo CTA either before TOF MRA or after Dotarem-enhanced MRA. CTA will be used as standard of truth.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TOF MRA Followed by Dotarem-enhanced MRA</title>
          <description>Each patient will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem-enhanced MRA.
Each patient will be scheduled to undergo CTA either before TOF MRA or after Dotarem-enhanced MRA. CTA will be used as standard of truth.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="222"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="108"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="114"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="64.8" spread="11.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="117"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="81"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colombia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Argentina</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Mexico</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Korea, Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Chile</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Technical Failure Rate</title>
        <description>Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-060).</description>
        <time_frame>2 - 28 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dotarem-enhanced MRA</title>
            <description>Patients benefiting from an MRA after Dotarem IV administration</description>
          </group>
          <group group_id="O2">
            <title>TOF MRA</title>
            <description>Patients benefiting from an MRA with no contrast medium administration</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="198"/>
                  <measurement group_id="O2" value="198"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of arterial segments analyzed</title>
            <units>arterial segments</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2772"/>
                  <measurement group_id="O2" value="2772"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Technical Failure Rate</title>
            <description>Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-060).</description>
            <units>percentage of arterial segments</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Reader 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.65" lower_limit="3.87" upper_limit="5.44"/>
                  <measurement group_id="O2" value="29.44" lower_limit="27.74" upper_limit="31.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.77" lower_limit="1.28" upper_limit="2.26"/>
                  <measurement group_id="O2" value="16.70" lower_limit="15.31" upper_limit="18.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.20" lower_limit="1.65" upper_limit="2.75"/>
                  <measurement group_id="O2" value="18.54" lower_limit="17.10" upper_limit="19.99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity and Specificity at Patient Level and at Segment Level Excluding Non-assessable Segments</title>
        <time_frame>2-42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Predictive Values of Dotarem-enhanced MRA and TOF MRA at Patient Level and at Segment Level</title>
        <time_frame>2 - 42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inter and Intra-readers Agreement at the Segment Level</title>
        <time_frame>2 -42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity</title>
        <description>Rate of true stenotic segments (i.e. with stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).</description>
        <time_frame>2-42 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dotarem-enhanced MRA</title>
            <description>Patients benefiting from an MRA after Dotarem IV administration</description>
          </group>
          <group group_id="O2">
            <title>TOF MRA</title>
            <description>Patients benefiting from an MRA with no contrast medium administration</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="197"/>
                  <measurement group_id="O2" value="197"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of number of arterial segments analyzed</title>
            <units>number of arterial segments</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2686"/>
                  <measurement group_id="O2" value="2686"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sensitivity</title>
            <description>Rate of true stenotic segments (i.e. with stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).</description>
            <units>percentage of stenotic segments</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Reader 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58.46" lower_limit="46.48" upper_limit="70.44"/>
                  <measurement group_id="O2" value="53.85" lower_limit="41.73" upper_limit="65.97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63.08" lower_limit="51.34" upper_limit="74.81"/>
                  <measurement group_id="O2" value="63.08" lower_limit="51.34" upper_limit="74.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53.85" lower_limit="41.73" upper_limit="65.97"/>
                  <measurement group_id="O2" value="49.23" lower_limit="37.08" upper_limit="61.38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity</title>
        <description>Rate of true non-stenotic segments (i.e. without stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).</description>
        <time_frame>2 - 42 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dotarem-enhanced MRA</title>
            <description>Patients benefiting from an MRA after Dotarem IV administration</description>
          </group>
          <group group_id="O2">
            <title>TOF MRA</title>
            <description>Patients benefiting from an MRA with no contrast medium administration</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="197"/>
                  <measurement group_id="O2" value="197"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Number of arterial segments analyzed</title>
            <units>Number of arterial segments</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2686"/>
                  <measurement group_id="O2" value="2686"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Specificity</title>
            <description>Rate of true non-stenotic segments (i.e. without stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).</description>
            <units>percentage of non-stenotic segments</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Reader 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.13" lower_limit="97.61" upper_limit="98.65"/>
                  <measurement group_id="O2" value="85.43" lower_limit="84.07" upper_limit="86.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.51" lower_limit="98.05" upper_limit="98.98"/>
                  <measurement group_id="O2" value="90.39" lower_limit="89.26" upper_limit="91.51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.63" lower_limit="98.18" upper_limit="99.07"/>
                  <measurement group_id="O2" value="90.42" lower_limit="89.30" upper_limit="91.55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of the Different Reasons for Technical Failure for Both MRA Procedures</title>
        <time_frame>2 -42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Images of Both MRA Procedures</title>
        <time_frame>2 - 42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of Diagnostic Confidence for Both MRA Procedures</title>
        <time_frame>2 -42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Size of Stenoses for All Imaging Procedures (MRA and Gold Standard)</title>
        <time_frame>2 -42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Examination</title>
        <time_frame>2-42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of the Recommended Clinical Management</title>
        <time_frame>2 -42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <time_frame>0 - 42 days</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Sampling</title>
        <time_frame>24 hours after Dotarem injection</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerance at the Injection Site</title>
        <time_frame>24 hours after Dotarem injection</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected since the patient signing the patient consent form till the end of the last visits, maximum duration is 42 days.</time_frame>
      <desc>Adverse Events reported during the 24 hours following TOF, 24 hours following Dotarem-enhanced MRA and 24 hours following CTA and Adverse Events in discontinued patients without Dotarem administration are described. Participants at risk were subjects exposed to Dotarem administration.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dotarem MRA</title>
          <description>Patients benefiting from a MR angiography after an IV administration of Dotarem</description>
        </group>
        <group group_id="E2">
          <title>TOF MRA</title>
          <description>Patients benefiting from a MR angiography with no contrast medium administration</description>
        </group>
        <group group_id="E3">
          <title>Computerized Tomography Angiography (CTA)</title>
          <description>Patients benefiting from a CT angiography with an IV injection of iodinated contrast medium</description>
        </group>
        <group group_id="E4">
          <title>Patients Discontinued Without Dotarem Administration</title>
          <description>Patients withdrawn before administration of Dotarem whatever the reason</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>not related to Dotarem administration</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>not related to Dotarem administration</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <description>not related to Dotarem administration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <description>not related to Dotarem administration</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neutrophil Count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Pierre Desché, MD - VP Head of Development, Medical and Regulatory Affairs</name_or_title>
      <organization>Guerbet</organization>
      <phone>+33 1 45 91 50 00</phone>
      <email>pierre.desche@guerbet-group.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
